Home / Sources / Select Committees / Eleventh Report - The rollout of the COVID-19 vaccine progr…
Index live · Last sync 23 May 2026
Source · Select Committees · Public Accounts Committee

Eleventh Report - The rollout of the COVID-19 vaccine programme in England

Public Accounts Committee HC 258 Published 13 July 2022
Report Status
Government responded
Conclusions & Recommendations
32 items (9 recs)
Government Response
AI assessment · 13 of 32 classified
Accepted 7
Not Addressed 2
Rejected 4
Filter by: Clear

Recommendations

4 results
5 Rejected

After starting with a portfolio of seven candidates, the UK’s vaccine supply for 2022 and...

Recommendation
After starting with a portfolio of seven candidates, the UK’s vaccine supply for 2022 and 2023 now relies primarily on just two, yet many of the risks that the ‘portfolio’ approach was intended to mitigate remain. The UK’s portfolio strategy … Read more
Government Response Summary
The government disagrees with the recommendation to review the future procurement strategy for COVID-19 vaccines, stating that the current strategy is kept under constant review with expert advice. They cite agreements with developers that give access to updated vaccines and bivalent vaccines having received regulatory approval.
HM Treasury
View Details →
10 Rejected

The vaccine programme still has some issues to address.

Recommendation
The vaccine programme still has some issues to address. In England, 2.98 million adults were still unvaccinated at the end of May 2022. Analysis by UKHSA has confirmed that full and booster vaccination reduces the risk of someone falling seriously … Read more
Government Response Summary
The government disagrees with the recommendation to set a challenge to reduce the number of unvaccinated adults to 2.5 million and achieve 80% booster uptake, arguing it is moving away from target-based approaches.
HM Treasury
View Details →
19 Rejected

Since then, out of the original portfolio of seven candidates, six have been approved for...

Recommendation
Since then, out of the original portfolio of seven candidates, six have been approved for use in the UK to date.44 But with six vaccines to choose from, it is noteworthy that only three—AstraZeneca, Pfizer and Moderna—have actually been deployed … Read more
Government Response Summary
The government disagrees with the recommendation to review the future procurement strategy for COVID-19 vaccines, stating that the current strategy is kept under constant review with expert advice. They cite agreements with developers that give access to updated vaccines and bivalent vaccines having received regulatory approval.
HM Treasury
View Details →
21 Rejected

The Taskforce also told us that the COVID-19 vaccine market was still developing and that...

Recommendation
The Taskforce also told us that the COVID-19 vaccine market was still developing and that it considered many different factors when deciding which vaccines to procure, including the evolution of the virus and improved learning about different types of vaccines … Read more
Government Response Summary
The government disagrees with the recommendation to review the future procurement strategy for COVID-19 vaccines, arguing that the current portfolio approach is constantly reviewed with clinical and commercial expertise.
HM Treasury
View Details →